Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chris Parker

Showing results (1-10 of 170) with videos related to

Pageof 17
Sort By:
ESMO Open|November 16, 2018
Report from the ESMO 2018 presidential symposium-Radiotherapy to the primary tumour for men with newly diagnosed metastatic prostate cancer: survival results from STAMPEDEChris Parker
Lancet (London, England)|January 27, 2012
What (if anything) to do about low-risk prostate cancerChris Parker
European Urology|December 13, 2007
Editorial comment on: Prospective evaluation of quality of life in prostate cancer patients receiving combined treatment of postoperative radiotherapy plus androgen suppression for PT3 or positive resection margin after radical prostatectomyChris Parker
European Urology|May 31, 2008
Words of wisdom. Re: needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalenceChris Parker
European Urology|November 28, 2017
Re: Effect of Longer-interval Versus Standard Dosing of Zoledronic Acid on Skeletal Events in Patients with Bone MetastasesChris Parker
The Lancet. Oncology|March 29, 2011
Androgen deprivation before prostate radiotherapy: how long is long enough?Chris Parker
European Urology|March 2, 2016
Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016;70:21-30Chris Parker
The Lancet. Oncology|February 6, 2004
Active surveillance: towards a new paradigm in the management of early prostate cancerChris Parker
Mental Health Today (Brighton, England)|November 13, 2008
Coming out of the shadowsChris Parker
Pest Management Science|February 12, 2009
Observations on the current status of Orobanche and Striga problems worldwideChris Parker
Pageof 17

Showing results (1-10 of 170) with videos related to

Sort By:
Pageof 17
ESMO Open|November 16, 2018
Report from the ESMO 2018 presidential symposium-Radiotherapy to the primary tumour for men with newly diagnosed metastatic prostate cancer: survival results from STAMPEDEChris Parker
Lancet (London, England)|January 27, 2012
What (if anything) to do about low-risk prostate cancerChris Parker
European Urology|December 13, 2007
Editorial comment on: Prospective evaluation of quality of life in prostate cancer patients receiving combined treatment of postoperative radiotherapy plus androgen suppression for PT3 or positive resection margin after radical prostatectomyChris Parker
European Urology|May 31, 2008
Words of wisdom. Re: needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalenceChris Parker
European Urology|November 28, 2017
Re: Effect of Longer-interval Versus Standard Dosing of Zoledronic Acid on Skeletal Events in Patients with Bone MetastasesChris Parker
The Lancet. Oncology|March 29, 2011
Androgen deprivation before prostate radiotherapy: how long is long enough?Chris Parker
European Urology|March 2, 2016
Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016;70:21-30Chris Parker
The Lancet. Oncology|February 6, 2004
Active surveillance: towards a new paradigm in the management of early prostate cancerChris Parker
Mental Health Today (Brighton, England)|November 13, 2008
Coming out of the shadowsChris Parker
Pest Management Science|February 12, 2009
Observations on the current status of Orobanche and Striga problems worldwideChris Parker
Pageof 17